Latest news for Zealand Pharma (OTC:ZLDPF) Stock

Zealand Pharma A/S is a biotechnology company. It is focused on the discovery, design, and development of peptide-based medicines. The company's product pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The company has out-licensed a peptide program to Boehringer Ingelheim that has been moved ahead into early clinical development: a once-weekly novel dual-acting GLP-1/glucagon agonist for the treatment of obesity and/or Type 2 diabetes.

weight loss ai

Biotech

News

Health Care

Markets

ETFs

General

NONOF

ZLDPF

As per the official press release, the 16-week trial aimed to evaluate the safety, tolerability, and clinical effects of the drug called petrelintide.

Move Aside Ozempic, WeGovy: Denmark&#39;s New Drug Just Showed Positive Results For Weightloss

Small Cap

Boehringer Ingelheim and Zealand Pharma A/S (OTC: ZLDPF) announced that patients treated with BI 456906 

Obesity Drug Achieves ~15% Weight Loss - Zealand Pharma-Boehringer Ingelheim Partnered Drug May Compete With Novo Nordisk, Eli Lilly

ZEALAND PHARMA A/S ORD by Zealand Pharma A/S

Zealand Pharma A/S

In a report released today, Julian Harrison from BTIG maintained a Buy rating on Zealand Pharma (ZLDPF – Research Report), with a price target of D...

Zealand Pharma (ZLDPF) Receives a Buy from BTIG

Zealand Pharma: Weight Loss Drug Petrelintide Is Not A 'Me Too' Advancement

Jefferies analyst Lucy Codrington maintained a Buy rating on Zealand Pharma (ZLDPF – Research Report) on June 28 and set a price target of DKK1,100...

Jefferies Remains a Buy on Zealand Pharma (ZLDPF)

How To Pick Top Pharma Stocks: Novo Nordisk And More

Global Anti-Obesity Market Analysis: Key Trends And Insights

Study links GLP-1 drugs, metformin to lower risk of certain cancers

ClearBridge International Growth EAFE Strategy Q2 2024 Commentary

In a report released yesterday, Laura Hindley from Berenberg Bank maintained a Buy rating on Zealand Pharma (ZLDPF – Research Report), with a price...

Berenberg Bank Remains a Buy on Zealand Pharma (ZLDPF)

This weight loss stock is the best alternative to Eli Lilly, Novo - SA Sentiment

These are the weight loss drug stocks with the most upside - SA Sentiment Survey

AAGIY

AAIGF

ABBNY

ABBV

ABLZF

AMGN

ARGNF

ARGX

ASML

ASMLF

ATLCY

ATLFF

ATLKY

ATLPF

AZNCF

BBVA

BBVXF

BIIB

BVRDF

BVVBY

CFCV

CMPGF

CMPGY

CMSQF

CMSQY

CRBP

DGEAF

DLMAF

DSKYF

DSNKY

EADSF

EADSY

FBCG

GILD

GPCR

INFR

LLDTF

LLOBF

LRGE

LVMHF

LVMUY

MELI

NCSYF

NICE

NVDA

NVSEF

NVTAQ

OCPNF

OLYMY

PACB

PPRUF

PPRUY

PTCT

PUIGF

RACE

REGN

RHHBF

RHHBY

RHHVF

SSDOF

SSDOY

TERN

TEVA

TKPHF

TOELF

TOELY

TSMWF

UNLYF

VKTX

VTRS

VTYX

YLDE

ZLAB

Zealand Pharma

<p>Danish biotech company <strong>Zealand Pharma A/S</strong> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/ZLDPF#OTC">ZLDPF</a>) has announced encouraging topline results from a Phase 1b multiple ascending dose (MAD) trial of its weight management drug, petrelintide. The trial results were released on Thursday and comes at a time when the weightloss drug market is experiencing domination of another Danish pharmaceutical company Novo Nordisk (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) (OTC:<a class="ticker" href="https://www.benzinga.com/stock/NONOF#OTC">NONOF</a>) which produces Ozempic and WeGovy.</p>



<p><strong>What Happened: </strong>As per the official press release, the 16-week trial aimed to evaluate the safety, tolerability, and clinical effects of petrelintide. The drug, designed for weight management, demonstrated &#8220;significant and clinically meaningful reductions in body weight with a very favorable tolerability profile,&#8221; stated<strong> David Kendall, </strong>MD, Chief Medical Officer of Zealand Pharma.</p>



<p>The study involved 48 participants, predominantly male, who received 16 weekly doses of either petrelintide or a placebo. The average body weight decreased by 8.6% among participants who completed treatment with high dose petrelintide, compared to a 1.7% decrease in the placebo group.</p>



<p>Petrelintide was well received, with no serious or severe adverse events reported. Zealand Pharma plans to initiate a Phase 2b clinical trial of petrelintide later in 2024.</p>



<p><em>See Also: <a href="https://www.benzinga.com/government/24/06/39382435/medicare-agency-to-end-advance-payments-following-unitedhealth-cyberattack?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Medicare Agency To End Advance Payments Following UnitedHealth Cyberattack</a></em></p>



<p><strong>Why It Matters: </strong>The global market for <a href="https://www.benzinga.com/markets/equities/24/05/39057150/weight-loss-drug-forecasts-skyrocket-to-150b-as-novo-nordisk-eli-lilly-ramp-up-supply">weight-loss drugs</a> is projected to reach a staggering $150 billion by the early 2030s, a significant leap from the previous forecast of $100 billion. This surge is attributed to the growing availability of weight-loss medications from companies like<strong> Novo Nordisk</strong> and <strong>Eli Lilly and Co </strong>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>).</p>



<p>Novo Nordisk, the maker of Ozempic, is reportedly set to overtake <a href="https://www.benzinga.com/markets/equities/24/06/39295950/ozempic-maker-novo-nordisk-closes-in-on-lego-as-denmarks-most-valuable-brand-report">Denmark's iconic toymaker,</a><strong> Lego A/S,</strong> as the nation's most valuable brand, thanks to the surging popularity of its weight-loss drugs on a global scale.</p>



<p><strong>Price Action: </strong>Following the news, Zealand stocks closed about 10% higher at $100 on the OTC, according to <a href="https://pro.benzinga.com">Benzinga Pro</a>.</p>



<p><em>Read Next: <a href="https://www.benzinga.com/markets/cannabis/24/06/39401689/desantis-faces-backlash-over-email-blast-to-2m-people-including-medical-marijuana-patients-who-c?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">DeSantis Faces Backlash Over Email Blast To 2M People Including Medical Marijuana Patients Who Cite Privacy Concerns, Misuse Of Information</a></em></p>



<p><em>Image via Midjourney</em></p>



<p>This story was generated using <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and edited by <u><a href="https://www.benzinga.com/topic/Pooja-Rajkumari" target="_blank" rel="noreferrer noopener">Pooja Rajkumari</a></u></p>

Move Aside Ozempic, WeGovy: Denmark's New Drug Just Showed Positive Results For Weightloss

Zealand Pharma Says Data From Part 1 Of Multiple Ascending Dose Trial With ZP8396 For Obesity Showed Mean Weight Loss Of 5.3%, 5.1% at 0.6, 1.2 mg doses Versus 2.6%, 3.6%, 4.2% at doses of 0.7, 1.4, 2.4 mg doses, Already Reported

<p><strong>Boehringer Ingelheim</strong>&nbsp;and&nbsp;<strong>Zealand Pharma A/S</strong>&nbsp;(OTC:<a class="ticker" href="https://www.benzinga.com/stock/ZLDPF#OTC">ZLDPF</a>) announced that patients treated with BI 456906&nbsp;<a class="editor-rtfLink" href="https://www.boehringer-ingelheim.com/phase-ll-trial-results-in-obesity-or-overweight" style="color:#4a6ee0; background:transparent; margin-top:0pt; margin-bottom:0pt" target="_blank">achieved</a>&nbsp;up to 14.9% weight loss after 46 weeks, using the planned maintenance dose. The data comes from&nbsp;<a class="editor-rtfLink" href="https://clinicaltrials.gov/ct2/show/NCT04667377" style="color:#4a6ee0; background:transparent; margin-top:0pt; margin-bottom:0pt" target="_blank">387</a>&nbsp;patients.</p>

<p>The phase 2 clinical trial evaluating the novel glucagon/GLP-1 receptor dual agonist BI 456906 in people living with obesity or overweight without type 2 diabetes met its primary endpoint.&nbsp;</p>

<p>Full data will be presented at the 2023 American Diabetes Association&#39;s 83rd Scientific Sessions.</p>

<p>Paola Casarosa, head of therapeutic areas at Boehringer Ingelheim,&nbsp;<a class="editor-rtfLink" href="https://www.reuters.com/business/healthcare-pharmaceuticals/zealand-boehringers-drug-meets-main-weight-loss-goal-mid-stage-trial-2023-05-10/" style="color:#4a6ee0; background:transparent; margin-top:0pt; margin-bottom:0pt" target="_blank">told</a>&nbsp;Reuters the partners are in discussion with regulators about the design of a planned follow-up trial in the third and last phase of testing.</p>

<p>The demand for weight-loss treatments such as&nbsp;<strong>Novo Nordisk A/S&#39;s&nbsp;</strong>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) Wegovy, or potentially&nbsp;<strong>Eli Lilly And Co&#39;s</strong>&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) Mounjaro, could support as many as ten competing products with annual sales reaching up to $100 billion within a decade, mainly in the United States, industry executives and analysts said.</p>

<p>Lilly&#39;s tirzepatide reduced patients&#39; weights by an average of 16%, 21.4%, and 22.5% at the respective doses, compared to just 2.4% on placebo in a study with&nbsp;<a class="editor-rtfLink" href="https://www.benzinga.com/general/biotech/22/04/26873755/lillys-tirzepatide-shows-up-to-22-5-weight-loss-in-new-phase-3-readout" style="color:#4a6ee0; background:transparent; margin-top:0pt; margin-bottom:0pt" target="_blank">over 2,500 participants</a>.</p>

<p>A late-stage trial showed that Novo&#39;s Wegovy helped patients obtain a weight loss of about 15-17% over 68 weeks, depending on patient subgroups in the study.</p>

<p>Casarosa said the results could not be directly compared because of trial design and size differences.</p>

<p>UBS analyst Michael Leuchten noted the initial weight-loss readout was below that of Mounjaro and Phase 2 trials of another Novo drug candidate, CagriSema, but said a lower price could pave the way into a profitable market segment.</p>

<p><em>Photo by Vidmir Rais via Pixabay</em></p>
 

<div>
	With reference to the company announcement no. 29/2017 dated August 1, 2017 regarding the filing of a Form F-1 registration statement, including a preliminary prospectus, and commencement of an initial public offering of American Depositary Shares (&quot;ADSs&quot;) on The Nasdaq Global Select Market in the United States under the symbol &quot;ZEAL&quot; (the &quot;Offering&quot;), Zealand Pharma A/S (OTC:<a class="ticker" href="/stock/ZLDPF#OTC">ZLDPF</a>) announces that the board of directors of Zealand (the &quot;Board&quot;) has today determined (i) to increase the size of the Offering from up to 3,900,000 ADSs to a total of 4,375,000 ADSs, and to issue a total of 4,375,000 ADSs (excluding any ADSs that may be sold or issued as part of the Over-allotment Option (as defined below)) and a corresponding number of underlying new shares, and (ii) &nbsp;that the public offering price for the ADSs issued as part of the Offering is USD 17.87 per ADS, corresponding to a subscription price of DKK 112.58 per underlying new share. The Offering is expected to be completed on August 14, 2017 (subject to the satisfaction of customary closing conditions).</div>
<div>
	&nbsp;</div>
<div>
	The Form F-1 registration statement, including the preliminary prospectus, related to the Offering has been declared effective by the U.S. Securities and Exchange Commission. The Offering of the ADSs is being made only by means of such U.S. prospectus. A copy of the final U.S. prospectus related to the Offering may be obtained at no cost, when available, by visiting EDGAR on the U.S. Securities and Exchange Commission website (<a href="http://www.sec.gov" title="www.sec.gov">www.sec.gov</a>).</div>
<div>
	&nbsp;</div>
<div>
	Summary of the Offering:</div>
<div>
	&nbsp;</div>
<div>
	The Offering will consist of an offering of a total of 4,375,000 ADSs, corresponding to 4,375,000 underlying new shares (the &quot;New Shares&quot;), which in their entirety are expected to be subscribed for by Morgan Stanley &amp; Co. LLC and Goldman Sachs &amp; Co. LLC (the &quot;Book-running Managers&quot;), as representatives of the several Underwriters (as defined below), with an instruction to deliver such new shares to The Bank of New York Mellon acting as depositary for the underlying new shares in the Offering;</div>
<div>
	The public offering price is USD 17.87 per ADS, corresponding to a subscription price of DKK 112.58 per underlying New Share;</div>
<div>
	The Book-running Managers, as representatives of the several Underwriters (as defined below), have been granted an over-allotment option (the &quot;Over-allotment Option&quot;) to acquire an additional 656,250 ADSs, exercisable in whole or in part through September 7, 2017 of which up to 500,000 of the underlying shares will be delivered in the form of existing treasury shares and 156,250 as new shares (the latter, the &quot;Over-allotment Shares&quot;);</div>
<div>
	Upon issue of the New Shares underlying the ADSs, the market capitalization of Zealand will be approximately DKK 3,595,749,012 assuming no exercise of the Over-allotment Option and approximately DKK 3,669,630,293 assuming full exercise of the Over-allotment Option;</div>
<div>
	The New Shares underlying the ADSs will correspond to 14.31% of Zealand&#39;s entire share capital assuming no exercise of the Over-allotment Option and 14.75% of Zealand&#39;s entire share capital assuming full exercise of the Over-allotment Option;</div>
<div>
	Gross proceeds from the Offering will amount to DKK 492,541,875 million assuming no exercise of the Over-allotment Option and DKK 566,423,156 million assuming full exercise of the Over-allotment Option;</div>
<div>
	Allocation of the ADSs has been determined by the Board in consultation with the Book-running Managers</div>
 

Offerings

IPOs

Zealand Pharma Prices 4.735M ADS IPO on The Nasdaq Global Select Market @$17.87/ADS

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Comments

Zealand Pharma

News

Latest news for Zealand Pharma (OTC:ZLDPF) Stock

Friday, June 21, 2024

Monday, July 03, 2023

Wednesday, May 10, 2023

Wednesday, August 09, 2017